Home|Journals|Articles by Year

Directory for Medical Articles

Original Research

RMJ. 2018; 43(3): 471-474

Comparison of efficacy with & without Tamsulosin as medical adjuvant therapy after Extracorporeal shockwave lithotripsy in renal stone.

Aamir Ali Shaikh, Yassar Hussain Patujo, Ahmed Bux Shaikh, Nisar Ahmed Shaikh and Malik Hussain Jalbani.


Objective: To compare the efficacy with & without tamsulosin as medical adjuvant therapy after extracorporeal shockwave lithotripsy in renal stone.
Methodology: A total of 160 patients were enrolled in this Randomized control trial from January 17, 2013 to July 16, 2013, having single renal stone. They were divided in two groups by lottery method; Group A, received capsule tamsulosin 0.4mg/once daily and Group B received only diclofenac 50mg/twice daily. All underwent extracorporeal shockwave lithotripsy. Patients were called every 14 days for follow up with X-ray KUB and pain was assessed by analogue numerical score. Final outcome was taken at 8 weeks, those who has no stone, mild to no pain and no steinstrasse was considered efficacy positive.
Results: Mean age of patients was 31.29±9.06 years. Out of 160, 61(38.1%) were female and 99(61.9%) were male. Rate of stone clear ness was 90.6%. Regarding severity of pain, 54.4% had no pain, 26.3% had mild, 11.3% had moderate pain and 8.1% had severe pain. Absence of steinstrasse formation was 86.3% cases. Tamsulosin 0.4 mg was significantly high as compare to without Tamsulosin (93.8% vs. 62.5%; p 0.0005).
Conclusion: Extracorporeal Shockwave Lithotripsy in combination to Alpha-1 Blocker was more effective than ESWL alone.

Key words: Renal stone, Extracorporeal shockwave lithotripsy and Tamsulosin.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.